Skip to Content
Stock Analyst Update

Roche, Regeneron FVEs Hold After New REGN-COV2 Data

Based on the data, we've increased our assumed probability of approval for the REGN-COV2 antibody cocktail to 100% from 60%.

Mentioned: ,

We're maintaining our CHF 417/$57 fair value estimates for Roche (RHHBY) and $500 fair value estimate for Regeneron (REGN) following data from a trial of SARS-CoV-2 antibody cocktail REGN-COV2 in nonhospitalized patients. Overall, we think the preliminary descriptive analysis--which included data on the first 275 patients in the trial--reflects a strong profile and solid potential to benefit patients with high viral loads who have failed to form an immune response to the virus. Potential sales of REGN-COV2 would provider further support to Roche's established wide moat and Regeneron's narrow moat.

Based on the data, we've increased our assumed probability of approval for REGN-COV2 to 100% from 60%, but we're maintaining our assumption for $6 billion in peak sales in 2021 (split between Roche and Regeneron). We expect the Food and Drug Administration could grant emergency use authorization this fall. While Regeneron expects to have supply to treat 300,000 patients later this year as part of the $450 million U.S. government contract, it remains unclear how much the partners will be able to ramp supply in 2021 (initially 250,000 doses per month, according to Regeneron's call on Sept 29). We continue to see Regeneron shares as slightly overvalued, given significant advancement with vaccines and potential emergency use authorizations of multiple vaccines later this year.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.